I was afraid from the start that the patients in the “moderate to severe” category were too far into the disease process to take optimal advantage of Brilacidin’s anti-viral capabilities. But I felt that I had to trust that all the brains involved had reason to select the moderate to severe category. Now, given the results of this trial, I am not optimistic about the compassionate use cases. However, the mild to moderate cases should be in Brilacidin’s sweet spot. The two new drugs are both given orally (pills) but they both apparently have limited effectiveness as well as the potential for serious side effects. If Brilacidin excels in mild to moderate, it will still be the safest drug capable of making a difference for patients suffering from Covid-19 and possibly many other viruses.

Based on this and the many other irons IPIX has in the fire, I added almost 10% to my holdings today.